MARKET

DCTH

DCTH

Delcath Sys
NASDAQ
7.82
-0.15
-1.88%
After Hours: 7.82 0 0.00% 16:00 07/17 EDT
OPEN
7.92
PREV CLOSE
7.97
HIGH
8.03
LOW
7.50
VOLUME
299.46K
TURNOVER
0
52 WEEK HIGH
9.18
52 WEEK LOW
2.250
MARKET CAP
217.28M
P/E (TTM)
-2.9533
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at DCTH last week (0708-0712)?
Weekly Report · 3d ago
Weekly Report: what happened at DCTH last week (0701-0705)?
Weekly Report · 07/08 11:39
Weekly Report: what happened at DCTH last week (0624-0628)?
Weekly Report · 07/01 11:40
Craig-Hallum Initiates Coverage of Delcath Systems (DCTH) with Buy Recommendation
NASDAQ · 06/29 03:31
DELCATH SYSTEMS INC FILES FOR MIXED SHELF OF UP TO $150 MLN – SEC FILING
Reuters · 06/28 13:04
Delcath Systems Price Target Announced at $18.00/Share by Craig-Hallum
Dow Jones · 06/28 11:45
Delcath Systems Initiated at Buy by Craig-Hallum
Dow Jones · 06/28 11:45
Craig-Hallum Initiates Coverage On Delcath Systems with Buy Rating, Announces Price Target of $18
Benzinga · 06/28 11:35
More
About DCTH
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's products, HEPZATO KIT (Hepzato (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT) percutaneous hepatic perfusion (PHP) are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATO KIT is a drug/device combination product designed to administer high-dose chemotherapy directly into the liver while limiting systemic exposure and associated side effects. In Europe, the hepatic delivery system is a stand-alone medical device having the same device components as HEPZATO KIT, but without the melphalan hydrochloride and is approved for sale under the trade name CHEMOSAT. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).

Webull offers Delcath Systems Inc stock information, including NASDAQ: DCTH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DCTH stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DCTH stock methods without spending real money on the virtual paper trading platform.